August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO

“We are confident that this will mark the first steps toward a reduction of the duration of trastuzumab in many women with HER2-positive breast cancer,” says Helena M. Earl, MBBS, PhD, FRCP.

“Treating financial toxicity at the patient level is similar to treating a symptom like fatigue. You can try to prevent it, but to some degree, patients are going to experience it, and when they do, you need a plan,” says Yousuf Zafar, MD, MHS.

Interest in personalizing medicine in oncology is growing, so the American Society of Clinical Oncology (ASCO) titled its theme for the 2018 presidential address at the annual meeting, "Delivering Discoveries: Expanding the Reach of Precision Medicine."